Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is ...

Edward Bausch transformed the world of optics with groundbreaking inventions like the iris diaphragm shutter and advanced ...

Bausch & Lomb (NYSE:BLCO) rose 9% after a report about private equity interest in a takeover of the eyecare company. Private equity firms including Blackstone (BX), Advent International ...

Larry Biegelsen, an analyst from Wells Fargo, assigned the Buy rating on Bausch + Lomb Corporation (BLCO – Research Report). The associated price target remains the same with $23.00. Larry ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...

Bausch + Lomb rose in premarket trading Monday after the Financial Times reported that it is considering selling itself as a way to separate from Bausch Health, its indebted parent company.

The Opal platform offers eye care professionals a complementary tool for patients, featuring order tracking, appointment ...

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is exploring a potential sale and is seeing interest from private equity ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce ...